StockData
Vertex Pharmaceuticals Inc logo

Vertex Pharmaceuticals Inc

VRTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 4, 2026Score 15/3037% above fair value
$553.15−5.73 (-1.03%)

Close on Nov 2, 2026Market cap $140.20BP/E 32.2Yield –

Vertex Pharmaceuticals Level 3 contingent consideration liabilities by Quarter

Level 3 contingent consideration liabilities — Total fair value ($M) ($M)

QuarterlyAnnual

Vertex Pharmaceuticals Level 3 contingent consideration liabilities: $79.6M in Q2 2026, down 0.5% from a year earlier.

Latest, Q2 2026
79.6
Period ended Jun 30, 2026
Change on a year earlier
-0.5%
80 in Q2 2025
History
29 quarters
Since Q4 2018
Sources
27
Documents cited below

Where the Q2 2026 figure comes from

Source: Form 10-Q (filed 2026-08-04) ↗

Reported in Form 10-Q / 10-K Fair Value Measurements Note.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedLevel 3 contingent consideration liabilities — Total fair value ($M) ($M)Year on yearSource
Q2 2026Jun 30, 202679.6-0.5%Form 10-Q (filed 2026-08-04) ↗
Q1 2026Mar 31, 202679.2+0.1%Form 10-Q (filed 2026-05-05) ↗
Q4 2025Dec 31, 202579+2.7%Form 10-Q (filed 2026-08-04) ↗
Q3 2025Sep 30, 202578.10.0%Form 10-Q (filed 2025-11-04) ↗
Q2 2025Jun 30, 202580+2.8%Form 10-Q (filed 2025-08-05) ↗
Q1 2025Mar 31, 202579.1+2.3%Form 10-Q (filed 2025-05-06) ↗
Q4 2024Dec 31, 202476.9-0.6%Form 10-K (filed 2026-02-13) ↗
Q3 2024Sep 30, 202478.1-38.8%Form 10-Q (filed 2024-11-05) ↗
Q2 2024Jun 30, 202477.8-38.5%Form 10-Q (filed 2024-08-02) ↗
Q1 2024Mar 31, 202477.3-39.2%Form 10-Q (filed 2024-05-07) ↗
Q4 2023Dec 31, 202377.4-40.0%Form 10-K (filed 2025-02-13) ↗
Q3 2023Sep 30, 2023128+0.4%Form 10-Q (filed 2023-11-07) ↗
Q2 2023Jun 30, 2023127-2.5%Form 10-Q (filed 2023-08-02) ↗
Q1 2023Mar 31, 2023127-29.0%Form 10-Q (filed 2023-05-02) ↗
Q4 2022Dec 31, 2022129-30.8%Form 10-K (filed 2024-02-15) ↗
Q3 2022Sep 30, 2022127-32.5%Form 10-Q (filed 2022-10-28) ↗

Breakdown

What makes up level 3 contingent consideration liabilities

Cite this data

StockData. (2026). Vertex Pharmaceuticals Level 3 contingent consideration liabilities ($M), quarterly Q4 2018–Q2 2026 [Data set]. Compiled from Vertex Pharmaceuticals SEC filings and investor materials. https://stockdatahq.com/stocks/vrtx/kpis/cc-liab-tot

See every metric in the Vertex Pharmaceuticals KPI table. Data updated Nov 2, 2026.